Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PALO ALTO, Calif.: PALO ALTO, Calif., Oct. 1, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported that, in connection with the appointment of Erik Atkisson as Eiger's General Counsel...

Click to view original post